Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract] - Amin, A; Plimack, E R; Infante, J; Ernstoff, B; Rini, B I (J Clin Oncol, 2014)